MetaADEDB 2.0 @ LMMD
Tranylcypromine
(BKPRVQDIOGQWTG-FKXFVUDVSA-N)
Structure
SMILES
OS(=O)(=O)O.N[C@@H]1C[C@H]1c1ccccc1.N[C@@H]1C[C@H]1c1ccccc1
Molecular Formula:
C18H24N2O4S
Molecular Weight:
364.459
Log P:
4.8310
Hydrogen Bond Acceptor:
6
Hydrogen Bond Donor:
4
TPSA:
135.02
CAS Number(s):
13492-01-8
Synonym(s)
1.
Tranylcypromine
2.
Jatrosom
3.
Parnate
4.
Transamine
5.
Tranylcypromine Sulfate
6.
trans-2-Phenylcyclopropylamine
7.
Sulfate, Tranylcypromine
8.
trans 2 Phenylcyclopropylamine
External Link(s)
MeSHD014191
PubChem Compound25267092
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Drug DependenceFAERS: 3US FAERS
2ThrombocytopeniaFAERS: 3US FAERS
3Alanine Aminotransferase IncreasedFAERS: 2US FAERS
4Aspartate Aminotransferase IncreasedFAERS: 2US FAERS
5Blood creatine phosphokinase increasedFAERS: 2US FAERS
6Completed SuicideFAERS: 2OFFSIDES
US FAERS
7DeliriumFAERS: 2US FAERS
8Drug ineffectiveFAERS: 2OFFSIDES
US FAERS
9HomicideFAERS: 2US FAERS
10AgitationFAERS: 1US FAERS
11Allergy to chemicalsFAERS: 1US FAERS
12AmnesiaFAERS: 1OFFSIDES
US FAERS
13AnxietyFAERS: 1OFFSIDES
US FAERS
14Blood glucose decreasedFAERS: 1US FAERS
15Cerebrovascular accidentFAERS: 1US FAERS
16DrowningFAERS: 1US FAERS
17Drug abuseFAERS: 1US FAERS
18Drug withdrawal syndromeFAERS: 1US FAERS
19DysarthriaFAERS: 1US FAERS
20Emotional distressFAERS: 1US FAERS
21ErythemaFAERS: 1US FAERS
22HemiplegiaFAERS: 1US FAERS
23Impaired work abilityFAERS: 1US FAERS
24Incorrect dose administeredFAERS: 1US FAERS
25Insulin C-peptide decreasedFAERS: 1US FAERS
26Intentional product use issueFAERS: 1US FAERS
27Mental impairmentFAERS: 1US FAERS
28Mental status changesFAERS: 1US FAERS
29PalpitationsFAERS: 1US FAERS
30Product substitution issueFAERS: 1US FAERS
31nervous system disorderFAERS: 1US FAERS
32AcanthosisOFFSIDES
33AdenomaOFFSIDES
34Adverse eventOFFSIDES
35Allergy to arthropod stingOFFSIDES
36AlopeciaOFFSIDES
37Altered visual depth perceptionOFFSIDES
38Androgenetic AlopeciaOFFSIDES
39Anti-erythropoietin antibody positiveOFFSIDES
40ApathyOFFSIDES
41ArthritisOFFSIDES
42ArthropathyOFFSIDES
43ArthroscopyOFFSIDES
44AstheniaOFFSIDES
45AthetosisOFFSIDES
46Basal cell carcinomaOFFSIDES
47Biopsy breast abnormalOFFSIDES
48Blood phosphorus increasedOFFSIDES
49Body TemperatureOFFSIDES
50Cardioactive drug levelOFFSIDES
51Cataract operationOFFSIDES
52CataractOFFSIDES
53Chest wall painOFFSIDES
54ChromaturiaOFFSIDES
55ClonusOFFSIDES
56Color blindnessOFFSIDES
57Compression fractureOFFSIDES
58ConfabulationOFFSIDES
59Counterfeit product administeredCanada Vigilance: 1Canada Vigilance
60Decreased LibidoOFFSIDES
61DiplopiaOFFSIDES
62DiverticulitisOFFSIDES
63DrowsinessOFFSIDES
64Drug addictOFFSIDES
65Drug withdrawal headacheOFFSIDES
66Dysthymic DisorderOFFSIDES
67EczemaOFFSIDES
68Electroconvulsive TherapyOFFSIDES
69EnterocolitisOFFSIDES
70ExcoriationOFFSIDES
71Eye RednessOFFSIDES
72Feeling abnormalOFFSIDES
73HerniaOFFSIDES
74Hormone level abnormalOFFSIDES
75HyperreflexiaOFFSIDES
76HypomaniaOFFSIDES
77Impaired driving abilityOFFSIDES
78IncontinenceOFFSIDES
79Labile hypertensionOFFSIDES
80LacerationOFFSIDES
81Lesion excisionOFFSIDES
82LethargyOFFSIDES
83Leukopenia neonatalOFFSIDES
84MalabsorptionOFFSIDES
85Metanephrine urine increasedOFFSIDES
86Multiple drug overdose intentionalOFFSIDES
87Muscle WeaknessOFFSIDES
88Muscle necrosisOFFSIDES
89Musculoskeletal stiffnessOFFSIDES
90Myoclonic EpilepsyOFFSIDES
91NeurodermatitisOFFSIDES
92Neuroleptic Malignant SyndromeOFFSIDES
93Neurological decompensationOFFSIDES
94OpisthotonusOFFSIDES
95Oropharyngeal discomfortOFFSIDES
96OverdoseOFFSIDES
97PainOFFSIDES
98Performance status decreasedOFFSIDES
99Peroneal nerve injuryOFFSIDES
100Pharmaceutical product complaintOFFSIDES
101Pharyngeal lesionOFFSIDES
102Poor quality sleepOFFSIDES
103Post procedural cellulitisOFFSIDES
104Product complaintCanada Vigilance: 1Canada Vigilance
105Renal ColicOFFSIDES
106Renal cystOFFSIDES
107Respiratory FailureOFFSIDES
108Risus sardonicusOFFSIDES
109Suspected counterfeit productCanada Vigilance: 1Canada Vigilance
110Ultrasound breast abnormalOFFSIDES
111Visual disturbanceOFFSIDES
112Weight GainOFFSIDES
113treatment failureOFFSIDES
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120234

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.